# Mannkind Corp (MNKD)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/mannkind-corp/ JSON: https://steadybase.io/company/mannkind-corp.json Checked Nov 10, 2026. Latest filing read: Nov 5, 2026.

## Company

- Legal name: MANNKIND CORP
- Ticker: MNKD (Nasdaq)
- SEC CIK: 0000899460
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Danbury, CT
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: mannkindcorp.com
- LinkedIn: https://www.linkedin.com/company/mannkind-corporation
- Next earnings date: Feb 3, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $349.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/0001193125-26-073516-index.html
- Operating income: $38.8M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/0001193125-26-073516-index.html
- Net income: $5.9M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/0001193125-26-073516-index.html
- SG&A: $144.1M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/0001193125-26-073516-index.html
- Employees: 592 as of , as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Shares outstanding: 321,640,118 as of Oct 23, 2026 (10-Q filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526449776/0001193125-26-449776-index.html
- Auditor: Deloitte & Touche LLP, Los Angeles, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm

## Business

We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $349.0M | $38.8M | $5.9M | $144.1M |
| Dec 31, 2024 | $285.5M | $72.6M | $27.6M | $94.3M |
| Dec 31, 2023 | $199.0M | $8.7M | -$11.9M | $94.3M |
| Dec 31, 2022 | $99.8M | -$64.1M | -$87.4M | $91.5M |
| Dec 31, 2021 | $75.4M | -$47.0M | -$80.9M | $77.4M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/mannkind-corp.json

## Officers and directors

- Michael Castagna, Chief Executive Officer. LinkedIn: https://www.linkedin.com/in/michael-castagna-a15770. Source: Form 4 filed Jul 17, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526308133/0001193125-26-308133-index.htm
- Christopher B. Prentiss, Chief Financial Officer. LinkedIn: https://linkedin.com/in/chris-prentiss-7689872. Source: Form 4 filed Jul 17, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526308139/0001193125-26-308139-index.htm
- Dominic Marasco, R.Ph., President, Endocrine Business Unit. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- David Thomson, EVP Genl Counsel & Secretary. LinkedIn: https://linkedin.com/in/david-thomson-5193355. Source: Form 4 filed Jul 17, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526308131/0001193125-26-308131-index.htm
- Sanjay R. Singh, EVP Technical Operations. LinkedIn: https://linkedin.com/in/sanjaysinghbalyan. Source: Form 4 filed Jul 17, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526308132/0001193125-26-308132-index.htm
- Stuart A. Tross, Chief People & Workpl Officer. Source: Form 4 filed Jul 17, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526308134/0001193125-26-308134-index.htm
- Ajay Ahuja, Chief Medical Officer. LinkedIn: https://linkedin.com/in/ajay-ahuja-md-mba. Source: Form 4 filed Mar 25, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526124723/0001193125-26-124723-index.htm
- David B. Thomson, Ph.D., J.D., General Counsel and Corporate Secretary. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Stuart A. Tross, Ph.D., Executive Vice President, Human Resources. LinkedIn: https://www.linkedin.com/in/stuarttross. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Dominic Marasco, Pres, Endocrine Business Unit. Source: Form 4 filed Jul 17, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526308137/0001193125-26-308137-index.htm
- Anthony Hooper, director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Christine Mundkur, director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Jennifer Grancio, director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Michael A. Friedman, M.D., director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Ronald J. Consiglio, director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Sabrina Kay, Ed.D., director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- Steven B. Binder, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- David B. Thomson, Named in proxy. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526145613/mnkd-20260407.htm
- James S. Shannon, M.D., Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526145613/mnkd-20260407.htm
- JAMES S. SHANNON, M.D., MRCP (UK), Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/899460/000119312526145613/mnkd-20260407.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526449743/mnkd-20261105.htm
- Aug 21, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526361105/d118419d8k.htm
- Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-20260805.htm
- Jul 24, 2026: Item 3.02, Unregistered sales of equity securities; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm
- Jun 2, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/mnkd-20260529.htm
- May 28, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/mnkd-20260527.htm
- May 22, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526237183/mnkd-20260520.htm
- May 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-20260506.htm
- Feb 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-20260226.htm
- Nov 10, 2025: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312525273321/d25083d8k.htm

## Insider trades (Form 4)

- Sep 25, 2026: Steven B. Binder (Director) sold 39,051 shares, about $128,478. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526405736/0001193125-26-405736-index.htm
- Sep 10, 2026: Steven B. Binder (Director) sold 33,558 shares, about $127,856. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526391003/0001193125-26-391003-index.htm
- Aug 7, 2026: Steven B. Binder (Director) sold 39,051 shares, about $158,547. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526343016/0001193125-26-343016-index.htm
- Jul 17, 2026: David Thomson (EVP Genl Counsel & Secretary) sold 24,109 shares, about $97,641. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526308131/0001193125-26-308131-index.htm
- Jul 17, 2026: Steven B. Binder (Director) sold 52,485 shares, about $213,089. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526308129/0001193125-26-308129-index.htm
- May 12, 2026: Steven B. Binder (Director) sold 16,940 shares, about $55,733. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526222311/0001193125-26-222311-index.htm
- May 12, 2026: David Thomson (EVP Genl Counsel & Secretary) sold 3,033 shares, about $9,979. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526222310/0001193125-26-222310-index.htm
- Mar 10, 2026: Michael Castagna (Chief Executive Officer) bought 100,000 shares, about $259,000. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526100839/0001193125-26-100839-index.htm
- Jan 8, 2026: Stuart A. Tross (Chief People & Workpl Officer) sold 47,006 shares, about $297,548. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526009297/0001193125-26-009297-index.htm
- Dec 17, 2025: Michael Castagna (Chief Executive Officer) sold 65,804 shares, about $395,482. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312525327227/0001193125-25-327227-index.htm
- Dec 16, 2025: Michael Castagna (Chief Executive Officer) sold 42,116 shares, about $252,696. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312525321366/0001193125-25-321366-index.htm
- Dec 2, 2025: Michael Castagna (Chief Executive Officer) sold 107,920 shares, about $601,114. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312525308350/0001193125-25-308350-index.htm
- Dec 2, 2025: David Thomson (EVP Genl Counsel & Secretary) sold 147,780 shares, about $823,135. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312525308347/0001193125-25-308347-index.htm
- Nov 14, 2025: Sanjay R. Singh (EVP Technical Operations) sold 18,777 shares, about $94,448. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312525283569/0001193125-25-283569-index.htm
- Sep 16, 2025: Stuart A. Tross (Chief People & Workpl Officer) sold 47,000 shares, about $250,980. Source: https://www.sec.gov/Archives/edgar/data/899460/000119312525206517/0001193125-25-206517-index.htm

## What management said

- "The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them" Michael Castagna, Chief Executive Officer of MannKind (8-K filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/899460/000119312526449743/mnkd-ex99_1.htm

## Latest filings

- 8-K filed Aug 21, 2026: https://www.sec.gov/Archives/edgar/data/899460/000119312526361105/d118419d8k.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/899460/000119312526073516/mnkd-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/899460/000119312526335054/mnkd-20260630.htm
- DEF 14A filed Apr 7, 2026: https://www.sec.gov/Archives/edgar/data/899460/000119312526145613/mnkd-20260407.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/